Navigation Links
Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
Date:2/25/2008

SEOUL, South Korea, Feb. 25 /PRNewswire/ -- Dong-A PharmTech Co., Ltd. announced today that its European licensee, Dr. Falk Pharma, has initiated a 200 patient, phase 2 proof of concept clinical study to investigate the use of udenafil, a long acting phosphodiesterase type 5 inhibitor, for portal hypertension, an unmet medical need. The multi-center, European study is designed to investigate the safety and efficacy of udenafil in a study population of patients with portal hypertension resulting from liver disease.

Udenafil represents a potential new pharmacotherapy in the growing and underserved portal hypertension market which is projected to be 6 million people (US, EU and Japan) by 2010. Portal hypertension is the build-up of pressure in the portal vein (the vein carrying blood from the spleen and digestive tract to the liver). A major complication related to portal hypertension is variceal bleeding, where increased pressure causes veins in the esophagus to rupture and bleed. These episodes are fatal in 30% of patients and reoccurring in 70% of survivors

The most common cause of portal hypertension is cirrhosis of the liver due to alcohol abuse or hepatitis. Cirrhosis from chronic liver disease ranks among the top 15 causes of death worldwide and is expected to increase over the next 20 years due to the prevalence of hepatitis C and hepatitis B, and an increase in non-alcoholic fatty liver disease in development countries.

An estimated 170 million people are infected with hepatitis C and 350 million with hepatitis B globally. It is estimated that up to 25% of those who are chronically infected with hepatitis will develop portal hypertension due to cirrhosis.

The epidemic of obesity in developed countries will lead to a greater incidence of non-alcoholic fatty liver disease (NAFLD), Type II diabetes and high cholesterol which can progress to non-alcoholic steatohepatitis (NASH) and lead to fibrosis and cirrhosis. It is expected t
'/>"/>

SOURCE Dong-A PharmTech Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
2. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
3. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
4. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
5. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
6. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
7. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
8. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
9. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
10. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
11. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Today the U.S. Food and ... for the prevention of serogroup B meningococcal disease ... Pfizer,s vaccine Trumenba®, which received FDA approval in October, ... devastating disease. "I have heard over ...
(Date:1/23/2015)... lot of discussion in the medical community revolves around figuring ... conditions. As medical science advances, doctors and surgeons often feel ... consider to be more cutting edge. Yet, when it comes ... treatment that stands out as the best solution in all ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) ... health care leaders and a new study analyzing the impact of ... is a nationwide coalition working to educate policy makers and the ... the Capitol was focused on how the Iowa ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3
... , CLEVELAND, Nov. 30 DATATRAK International, Inc. (OTCQX: ... solutions for the clinical trials industry, today announced that PFC ... PFC will now have the ability to contract for DATATRAK,s ... product suite. In addition, PFC will also have access ...
... Breast-Specific Gamma Imaging (BSGI) has been proven to be ... carcinoma in situ (DCIS), a difficult to diagnose breast cancer. ... lesions independent of tissue density and discover very early stage ... of the Radiological Society of North America (RSNA), BSGI is ...
Cached Medicine Technology:PFC Pharma Joins DATATRAK's CRO Connect Program 2PFC Pharma Joins DATATRAK's CRO Connect Program 3PFC Pharma Joins DATATRAK's CRO Connect Program 4Breast-Specific Gamma Imaging Proves Highly Sensitive for the Detection of Ductal Carcinoma In Situ 2
(Date:1/22/2015)... Lynchburg, Va. (PRWEB) January 22, 2015 Liberty ... Health Counseling (M.A.) program from the Council for ... The program, part of Liberty’s Center for Counseling & ... Hawkins, founding dean of the university’s new School of Behavioral ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... TripAdvisor as the number one best large hotel for families ... world for their annual Travelers’ Choice Awards. , TripAdvisor ... website is home to millions of unbiased and honest traveler ...
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David Leadbetter ... to bestow a Juvent Sports Achievement award upon an ... The award commemorated and congratulated McKitrick for her record ... her first amateur tournament in 1979 and most recently ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3
... University and pediatric specialists at Baylor College of Medicine have ... as passkeys that allows drugs to enter cancer cells. ... of the journal Organic and Biomolecular Chemistry. ,All ... Cell walls, or membranes, form a protective cocoon around the ...
... that attacks healthy young people and can kill within 24 hours.// ... attempts to find a cure for the virulent disease, PVL-MRSA, that ... responsible for two deaths in Britain, experts fear we are in ... massive death toll if the superbug took hold in hospitals. ...
... particular brain region predicts whether people tend to be ... Medical Center study were published in the Sunday, Jan ... ,"Although understanding the function of this brain region may ... it may give clues to the origins of important ...
... researchers from Wake Forest University School of Medicine, Radiation Therapy ... tamoxifen can dramatically reduce the risk of both cancer recurrence ... ,"While these treatments are standard care for ... are less likely to receive them," said lead author Ann ...
... youngsters are contracting tuberculosis, especially those in their 20s, due ... according to a report. ,Last year about ... ,According to the report of the Korea ... in 2006, an average of 115 people per day. ...
... control over choosing their breast cancer surgeon were more likely ... at a hospital affiliated with an accredited cancer program, compared ... health plan, according to a study led by researchers at ... study looked at 1,844 women recently diagnosed with breast cancer ...
Cached Medicine News:Health News:Buckyballs Used as 'Passkey' into Cancer Cells 2Health News:Activation of a Particular Brain Region Predicts Altruism: Study 2Health News:Cancer Recurrence in Older Breast Cancer Patients Reduced By Radiation Therapy 2Health News:More Youngsters Get Tuberculosis 2Health News:Are Women Seeing the Most Experienced Breast Cancer Surgeons? 2
... Gel Bed dimensions: 7.5cm(w) x 10cm(l). ... casting in the unit. Gel bed ... blue, yellow, pink, purple, or green. ... and dual sided combs, and Flip-Lid versions ...
... Submerged horizontal gels offer many advantages ... a primary tool for the molecular biologist. ... readily dissipate heat. These gels allow sample ... by wicks or sample well dehydration. Horizontal ...
... with 7 x 10 cm tray and ... gel electrophoresis of nucleic acids in mini ... The system includes an electrophoresis cell, 7 ... gates, mini-gel caster, and two 1.5 mm ...
... cell GT system, with 7 x ... submerged horizontal gel electrophoresis of nucleic ... 10 cm agarose gels. The system ... 10 cm UV-transparent gel tray, casting ...
Medicine Products: